Harrow (HROW) Reaffirms 2026 Guidance, Is The Upside Already Priced In?

Event recap and why Harrow stock is in focus

Harrow (HROW) is back on investor radar after the company reiterated its 2026 revenue guidance of US$350 million to US$365 million and reported second quarter results that paired higher sales with a wider net loss.

The stock has risen over the past 3 months but is down over the past month. That backdrop makes the latest guidance and earnings release an important checkpoint for anyone tracking Harrow’s eyecare focused plans.

See our latest analysis for Harrow.

Against that backdrop, Harrow’s recent news sits on top of a mixed share price record, with the stock up 28.06% over the past 90 days but down 20.82% year to date. The five year total shareholder return of 314.26% highlights how sentiment has shifted over a longer horizon.

If you are comparing Harrow’s story with other opportunities in healthcare, this is a useful moment to scan a curated list of 42 healthcare AI stocks

After Harrow’s sharp 3 month gain and recent pullback, the real issue is timing. Does the current price already reflect its updated 2026 plans, or could patience offer a more attractive entry as valuation work unfolds next?

Most Popular Narrative: 42.2% Undervalued

Based on the most followed narrative, Harrow’s fair value of $68.38 sits well above the last close at $39.52, which frames the current valuation debate.

The rapidly growing demand for Harrow's portfolio of specialty ophthalmic drugs, particularly VEVYE, IHEEZO, and TRIESENCE, is positioned to accelerate further as aging populations and increased prevalence of chronic ocular diseases expand the baseline patient pool, supporting sustainable long-term revenue growth.

Read the complete narrative.

Want to see what underpins that gap between fair value and share price? The narrative leans on fast rising revenue, widening margins and a future earnings profile that assumes a different profit mix for Harrow.

Result: Fair Value of $68.38 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Harrow’s story can change quickly if heavy reliance on VEVYE, IHEEZO and TRIESENCE or ongoing U.S. drug pricing pressure affects revenue or margins.

Find out about the key risks to this Harrow narrative.

Next Steps

Given the mixed sentiment around Harrow, it makes sense to move quickly and review the underlying data for yourself. To see why some investors are focused on potential upside, take a closer look at the 2 key rewards.

Looking for more investment ideas beyond Harrow?

If Harrow has caught your attention but you want more options, use the Simply Wall Street Screener to quickly spot stocks that might better fit your goals.

• Target potential upside by scanning companies that combine quality fundamentals with appealing prices through the 50 high quality undervalued stocks.
• Build a steadier income stream by reviewing companies in the 11 dividend fortresses that aim to pair higher yields with stronger balance sheets.
• Reduce portfolio surprises by focusing on companies flagged in the 79 resilient stocks with low risk scores that show more resilient risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com